An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Launched by ALBIREO, AN IPSEN COMPANY · Jun 16, 2022

Keywords

ClinConnect Summary

This is a Phase 3, multi-center, open-label extension study to evaluate the long-term efficacy and safety of odevixibat in patients with Biliary Atresia (BA). Patients who completed treatment in the A4250-011 BOLD study and meet eligibility criteria for Study A4250-016 (BOLD-EXT) can participate. The duration of the treatment period is 104 weeks, followed by a 4-week Safety Follow-up Period. Patients who wish to continue receiving odevixibat after 104 weeks can remain on treatment in the optional extension period (OEP).

Up to 180 patients will be enrolled at approximately 70 sites in the N...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Completion of the 104-week Treatment Period of Study A4250-011
• • Signed informed consent by caregiver
• Exclusion Criteria:
• • Patients who were not compliant with study drug treatment or procedures in Study A4250-011 as per the investigator's discretion
• • Any conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
• • Known hypersensitivity to any components of odevixibat
• • Patients who are scheduled for a liver transplant or are likely to require a liver transplant in the immediate future based on the investigator's judgment